Measurements of cardiac troponin concentrations are at present universally accepted and recommended as the “gold standard” biochemical methods for diagnosis of acute myocardial infarction (AMI) in patients presenting with chest pain.  In addition, levels of cardiac troponin T (cTnT) and troponin I (cInI) provide useful prognostic information and can help to guide the management of acute coronary syndrome (ACS) patients.¹  Nonetheless, although the currently available troponins have a nearly absolute cardiac specificity, they are not disease specific and cannot be used to distinguish reversible from irreversible myocardial cell injury.

According to the new criteria of international cardiology societies,^1,2 the definitive ...